Filing Flows › Comparisons › MAZE vs PLX
Maze Therapeutics vs Protalix BioTherapeutics: MAZE and PLX compared
Maze Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $19.9M for Protalix BioTherapeutics (Q2 2026). Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -132.8%.
Where the money goes: MAZE and PLX
Maze Therapeutics (MAZE) · Q1 2026
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
Protalix BioTherapeutics (PLX) · Q2 2026
Protalix BioTherapeutics, Q2 2026: revenue $19.9M (+27% year over year), operating margin 23.5%, net earnings $3.8M, operating cash flow −$10.4M. The chart follows the revenue to costs, profit and cash.
| Maze Therapeutics (MAZE) | Protalix BioTherapeutics (PLX) | |
|---|---|---|
| Latest quarter | Q1 2026 | Q2 2026 |
| Revenue | $20.0M | $19.9M |
| Revenue growth, Y/Y | — | +27% |
| Operating margin | -132.8% | 23.5% |
| Net earnings | −$24.2M | $3.8M |
| Net margin | -121.0% | 19.0% |
| Operating cash flow | −$39.1M | −$10.4M |
Where the revenue comes from
Protalix BioTherapeutics
- GOODS: $19.8M (100%)
- LICENSE AND R&D SERVICES: $68K (0%)
Questions
Which is bigger, Maze Therapeutics or Protalix BioTherapeutics?
Maze Therapeutics is the larger company: $20.0M of revenue in its latest quarter (Q1 2026) against $19.9M for Protalix BioTherapeutics (Q2 2026).
Is Maze Therapeutics or Protalix BioTherapeutics growing faster?
Protalix BioTherapeutics is more profitable, with an operating margin of 23.5% against -132.8%.
More: Maze Therapeutics earnings · how Maze Therapeutics makes money · Protalix BioTherapeutics earnings · how Protalix BioTherapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed May 12, 2026; 10-Q filed Aug 12, 2026). Fiscal quarters can end on different dates. Not investment advice.